Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles. A Randomized Controlled Study

Next Previous
Trial Profile

Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles. A Randomized Controlled Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetrorelix (Primary) ; Chorionic gonadotropin (Primary) ; Ethinylestradiol/gestodene (Primary) ; Gonadotropins (Primary) ; Progesterone (Primary) ; Recombinant follicle-stimulating hormone (Primary) ; Triptorelin (Primary)
  • Indications Female infertility
  • Focus Therapeutic Use

Most Recent Events

  • 01 Mar 2021 Primary endpoint (Number of oocytes retrieved) has been met as per results published in the International Journal of Gynaecology and Obstetrics.
  • 01 Mar 2021 Results assessing single versus dual trigger for poor ovarian responders undergoing in vitro fertilization - intracytoplasmic sperm injection (IVF-ICSI) cycles using gonadotropin releasing hormone (GnRH) - agonist and human chorionic gonadotropin (hCG), published in the International Journal of Gynaecology and Obstetrics.
  • 08 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top